JapanÔÇÖs Astellas Pharma has agreed to buy OSI Pharmaceuticals for $4 billion in cash, having raised its bid by 11 percent. As a result of the deal, Tokyo-based Astellas will gain the worldÔÇÖs fourth best-selling lung cancer medicine and a US sales team for oncology drugs. Melville, New York-based OSI, which was founded in 1983, will give Astellas the Tarceva drug for cancer, a disease area the Japanese company has identified for growth.